ArticleBMC gastroenterology2025
Global burden of early-onset gallbladder and biliary tract cancer from 1990 to 2021.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AJournal of gastrointestinal oncology · 2026Article
- Burden of gallbladder and biliary tract cancer (GBTC) in the middle east and North Africa (MENA) from 1990 to 2021: from the global burden of disease (GBD).Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGallbladder and biliary tract cancer (GBTC) denotes a range of invasive tumors. Emerging evidence has revealed a rising trend in the incidence of early-onset GBTC (EOGBTC) patients, referring to individuals under the age of 50 years old. We conducted an epidemiological study to assess the disease burden of EOGBTC.
methodsData on EOGBTC from 1990 to 2021 were sourced from the Global Burden of Disease Study 2021. Average annual percentage changes (AAPCs) and age-standardized rates (ASRs) were calculated to assess overall trends in the burden of EOGBTC. Statistical models including decomposition analysis, health inequality analysis, and Nordpred were utilized in the research.
resultsThe study indicated over 24,555 prevalent cases, 13,611 new cases, and roughly 8777 deaths of EOGBTC in 2021. The global ASR of incidence and prevalence displayed increased trends, while the ASR of mortality and disability-adjusted life years (DALYs) were downward trends. East Asia and South Asia represented the heaviest disease burdens. The disease burden is mainly concentrated in the middle, low-middle, and low SDI regions. Decomposition analysis revealed that the primary influence of disease burden was population growth. Health inequalities showed improvement. Nordpred model forecasted that by 2040, global EOGBTC incidence and prevalence may steadily increase, while the deaths and DALYs display a general downward trend.
conclusionsThe overall burden of EOGBTC continues to be considerable, especially in regions with middle, low-middle, and low SDI levels. These findings underscore the necessity for innovative healthcare strategies to alleviate the burden faced by EOGBTC globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.